ZyVersa Therapeutics Announces Publication in the Journal, Hepatology, Highlighting the Role of NLRP3 Inflammasome-Mediated IL-18 in Development of Liver Fibrosis
July 17, 2023 07:38 ET
|
ZyVersa Therapeutics
Liver fibrosis is a progressive form of chronic liver injury mediated by persistent NLRP3 inflammasome activation in liver cells called hepatic stellate cells (“HSCs”), which leads to the development...
EnteroBiotix Initiates Phase 2 study of microbiome drug EBX-102 in liver cirrhosis and hepatic encephalopathy
March 28, 2023 03:00 ET
|
EnteroBiotix
GLASGOW, United Kingdom, March 28, 2023 (GLOBE NEWSWIRE) -- EnteroBiotix Limited (“EBX”), a clinical stage biotechnology company focussed on developing best-in-class full-spectrum microbiome...
BioVie Completes Patient Enrollment for its Phase 2a Clinical Trial of BIV201 in Refractory Ascites
February 06, 2019 08:00 ET
|
BioVie Inc.
LOS ANGELES, Feb. 06, 2019 (GLOBE NEWSWIRE) -- BioVie Inc. (OTCQB: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for liver disease, announced today...
Ocera Completes Enrollment of STOP-HE, a Phase 2b Study of OCR-002 in Hospitalized Patients with Hepatic Encephalopathy
December 07, 2016 09:05 ET
|
Ocera Therapeutics, Inc.
PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., Dec. 07, 2016 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (NASDAQ:OCRX), today announced it has completed enrollment in its Phase 2b STOP-HE...
Ocera to Present at the Stifel 2016 Healthcare Conference
November 09, 2016 09:05 ET
|
Ocera Therapeutics, Inc.
PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., Nov. 09, 2016 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (NASDAQ:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic...
Ocera to Present at the Ladenburg Thalmann 2nd Annual Healthcare Conference
September 20, 2016 09:10 ET
|
Ocera Therapeutics, Inc.
PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., Sept. 20, 2016 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (NASDAQ:OCRX), a clinical stage biopharmaceutical company focused on acute and...
Ocera to Present at the 15th Annual Needham Healthcare Conference
April 05, 2016 16:25 ET
|
Ocera Therapeutics, Inc.
PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., April 05, 2016 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (NASDAQ:OCRX), a clinical stage biopharmaceutical company focused on acute and...
Ocera to Present at BIO Investor Forum 2015
October 13, 2015 16:05 ET
|
Ocera Therapeutics, Inc.
PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., Oct. 13, 2015 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (NASDAQ:OCRX), a clinical stage biopharmaceutical company focused on acute and...
Ocera Therapeutics Secures $20 Million Debt Facility from Oxford Finance and Silicon Valley Bank
July 30, 2015 16:05 ET
|
Ocera Therapeutics, Inc.
PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., July 30, 2015 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (NASDAQ:OCRX), a clinical stage biopharmaceutical company focused on acute and...
Tranzyme Pharma Announces First Quarter 2013 Financial Results
May 09, 2013 16:30 ET
|
Ocera Therapeutics, Inc.
RESEARCH TRIANGLE PARK, N.C., May 9, 2013 (GLOBE NEWSWIRE) -- Tranzyme Pharma (Nasdaq:TZYM) ("Tranzyme"), a biopharmaceutical company focused on discovering, developing and commercializing novel,...